2630 — Vigonvita Life Sciences Co Income Statement
0.000.00%
Last trade - 00:00- HK$10.06bn
- HK$10.52bn
- KR₩12m
Annual income statement for Vigonvita Life Sciences Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 200 | 11.8 |
| Cost of Revenue | ||
| Gross Profit | 194 | 3.49 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 186 | 213 |
| Operating Profit | 13.6 | -201 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | 6.43 | -218 |
| Provision for Income Taxes | ||
| Net Income After Taxes | 6.43 | -218 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | 12.1 | -211 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | 12.1 | -211 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | 0.072 | -1.22 |